Table 2.
Immunological features in the study population.
| Pt | Hypogammaglobulinemia | CD20/mm^3 | SARS-CoV-2 vaccination | Pre-immunotherapy | Post-Immunotherapy | ||||
|---|---|---|---|---|---|---|---|---|---|
| IgM/IgA/IgG | Neutralizing Abs | Anti-Spike/RBD IgG | IgM/IgA/IgG | Neutralizing Abs | Anti-Spike/RBD IgG | ||||
| 1 | Yes | 1 | None | +/-/- | NA | NEG | -/-/+ | >1:640 | 8897.7 |
| 2 | Yes | 1 | None | -/-/- | NA | NEG | -/+/+ | 1:160 | 2961.1 |
| 3 | Yes | 0 | None | -/-/- | <1:10 | NEG | -/-/- | <1:10 | 181 |
| 4 | No | 1 | None | -/-/- | <1:10 | NEG | -/-/+ | 1:80 | 1159 |
| 5 | Yes | 0 | None | -/-/- | <1:10 | NEG | -/-/- | <1:10 | 67 |
| 6 | Yes | 1 | None | -/-/- | <1:10 | NEG | -/-/- | <1:10 | 197 |
| 7 | Yes | 1 | II Doses | -/-/- | <1:10 | NEG | -/+/+ | NA | NA |
| 8 | Yes | 2 | None | +/-/- | <1:10 | NEG | -/-/+ | >1:640 | >11360 |
| 9 | No | 0 | None | -/-/+ | NA | NA | -/-/+ | >1:640 | >11360 |
| 10 | Yes | 2 | II Doses | -/-/- | <1:10 | NEG | -/-/+ | NA | NA |
| 11 | Yes | 2 | I Dose | -/-/- | <1:10 | NEG | -/-/+ | NA | NA |
| 12 | Yes | 1 | None | -/-/- | <1:10 | 13.7 | -/-/+ | NA | NA |
| 13 | Yes | 24 | None | -/-/- | <1:10 | NEG | -/-/+ | 1:20 | 420.9 |
| 14 | Yes | 0 | II Doses | -/-/- | NA | NA | -/-/+ | NA | NA |
| 15 | Yes | 0 | None | NA | NA | NA | NA | NA | NA |
| 16 | Yes | 0 | None | -/-/- | NA | NEG | -/-/+ | NA | >11360 |
| 17 | NA | 0 | II Doses | -/-/- | NA | NEG | -/-/+ | NA | NA |
| 18 | Yes | 3 | II Doses | -/-/- | <1:10 | NEG | -/-/+ | >1:640 | >11360 |
| 19 | Yes | 24 | None | -/-/- | NA | NA | -/-/+ | NA | NA |
| 20 | Yes | 19 | III Doses | -/-/- | <1:10 | NEG | -/-/+ | NA | >11360 |
| 21 | Yes | 2 | None | -/-/- | NA | NA | -/-/+ | NA | NA |
Ig, immunoglobulins; Abs, antibodies; NA, not available. Anti-Spike/RBD IgG are expressed as Binding Antibody Units (BAU)/mL, values ≥7.1 are considered positive; neutralizing titers >1:10 are considered positive.